<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CD30 is a member of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor superfamily </plain></SENT>
<SENT sid="1" pm="."><plain>CD30 was originally described as a cell surface antigen on primary and cultured Hodgkin's and Reed-Sternberg cells </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, recombinant human CD30 ligand was expressed on the surface of CV-1/EBNA cells and tested for biologic activities on a variety of different CD30+ human <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>CD30 ligand enhanced Ig secretion of Epstein-Barr virus (EBV)-immortalized, CD30+ lymphoblastoid B-cell lines, but not Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> lines </plain></SENT>
<SENT sid="4" pm="."><plain>Recombinant CD30 ligand enhanced proliferation of "T-cell-like" <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>-derived cell lines and an adult T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell line, but not "B-cell-like" <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>-derived cell lines, CD30+, EBV-immortalized lymphoblastoid B-cell lines, or CD30+ and EBV+ <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, CD30 ligand mediated reduction of proliferation and viability, by induction of cytolytic cell <z:hpo ids='HP_0011420'>death</z:hpo>, of CD30+, large-cell anaplastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>Two new antibodies, M44 and M67, against the CD30 antigen demonstrated similar biologic activities to the CD30 ligand </plain></SENT>
<SENT sid="7" pm="."><plain>Taken together, these data demonstrate pleiotropic biologic activities of the CD30 ligand on different CD30+ <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines and indicate that the CD30-CD30 ligand interaction might have a pathophysiologic role in Hodgkin's and some non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>